Prosecution Insights
Last updated: November 20, 2026
Application No. 18/272,788

OCCULUSION SENSOR FOR PUMP ASSEMBLY

Non-Final OA §102§103
Filed
Jul 17, 2023
Priority
Jan 20, 2021 — provisional 63/139,664 +1 more
Examiner
STIMPERT, PHILIP EARL
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Becton, Dickinson and Company
OA Round
3 (Non-Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
571 granted / 902 resolved
-6.7% vs TC avg
Strong +49% interview lift
Without
With
+48.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
53 currently pending
Career history
970
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
49.3%
+9.3% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
28.5%
-11.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 902 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 29 September 2026 has been entered. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1 and 5-19 is/are rejected under 35 U.S.C. 103 as being unpatentable over US Pre-Grant Publication 2018/0214634 to Neftel et al. (Neftel hereinafter) in view of US Pre-Grant Publication 2016/0184516 to Shih et al. (Shih hereinafter). Regarding claim 1, Neftel teaches a medicament delivery system (1) comprising a reservoir (103) carrying a medicament (paragraph 3), a pump (100) to draw the fluid out of the reservoir for delivery, and an occlusion sensor (4, 13) connected (at least indirectly) to the reservoir that senses whether an occlusion is present (see e.g. paragraph 227). Furthermore, Neftel teaches a reservoir (103) which is flexible to at least a minimal extent, that the occlusion sensor includes a strain gauge (at least element 4, see paragraph 130), and that the sensor does not contact the medicament (see Fig. 1a, sensor shown on non-fluid contacting side of diaphragm at 13). Neftel does not teach a strain gauge bonded to an outer surface of the reservoir. Shih teaches another drug pump device (100) including a reservoir (104/106, 108) including a strain gauge bonded to an outer surface thereof (see paragraph 44, Figs. 5A and 5B). Shih teaches that this allows for reservoir volume determinations via detection of the strain (see paragraph 41 for general discussion). Furthermore, Shih teaches detection of malfunctions with the strain gauge or other system sensors (paragraph 50). One of ordinary skill in the art would have found it obvious before the effective filing date of the application to provide a reservoir with an embedded strain gauge as taught by Shih in order to allow for further detection of malfunctions. The examiner notes that, grammatically speaking, it is not clear whether the “occlusion sensor” or the “strain gauge” must perform the occlusion sensing, and herein interprets the claim to include either possibility. In the case that the occlusion sensor is only embodied by the strain gauge bonded to the reservoir, the examiner holds that it would have been obvious to perform occlusion detection via the strain gauge of Shih in the same manner that other malfunctions are detected. At the same time, the “including” language leaves open that there may be other sensors forming part of the “occlusion sensor”, and the strain gauge of Neftel would qualify as such and would be present in addition to the bonded sensor of Shih. Regarding claims 5-6, Neftel teaches a strain gauge (which detects strain, not pressure or current draw). Regarding claim 7, Neftel teaches determination of resistance and output thereof to control electronics (see e.g. paragraphs 335-343). To the extent necessary, the electronics and programming accomplishing this determination are considered herein to be a part of the occlusion sensor. Regarding claim 8, resistance decay is an inherent part of operating such an infusion device. Regarding claim 9, Neftel teaches that the occlusion is detected when the resistance does not decay according to a designated pattern (paragraph 354, e.g. decreasing resistance). Regarding claim 10, Neftel teaches a strain gauge which will detect changes in at least some forces across the reservoir, such as pressure forces therein. Additionally, the strain gauge (310) of Shih will detect changes in forces across the reservoir. Regarding claim 11, Neftel teaches that medicament exits the reservoir, upon which at least tension caused by the weight of the medicament will be reduced. Additionally, Shih teaches detection of tension by the reservoir strain gauge. Regarding claim 12, Shih teaches that the tension is measured along at least some axis. Regarding claim 13, Neftel teaches that the occlusion sensor (4, 13) is insensitive to forces along at least some lateral axes across the reservoir. Regarding claim 14, Neftel teaches that either as a result of the occlusion or the operation of the pump, the occlusion prevents the medicament from exiting the reservoir (see e.g. paragraph 248). Regarding claim 15, Neftel teaches that the occlusion sensor (4, 13) is at least indirectly bonded to an outer surface of the reservoir (see Fig. 1a). Regarding claim 16, Neftel teaches operation of a medicament delivery system (1) comprising a reservoir (103) carrying a medicament (paragraph 3), a pump (100) to draw the fluid out of the reservoir for delivery, and an occlusion sensor (4, 13) connected (at least indirectly) to the reservoir that senses whether an occlusion is present (see e.g. paragraph 227). Neftel teaches at least indirectly securing the occlusion sensor (4, 13) to an outer surface of the reservoir, operating the delivery system, measuring resistance (paragraphs 335-343) and providing such to control electronics, and determining the presence of occlusion (paragraph 248). Furthermore, Neftel teaches a reservoir (103) which is flexible to at least a minimal extent, that the occlusion sensor includes a strain gauge (at least element 4, see paragraph 130), and that the sensor does not contact the medicament (see Fig. 1a, sensor shown on non-fluid contacting side of diaphragm at 13). Neftel does not teach a strain gauge bonded to an outer surface of the reservoir. Shih teaches another drug pump device (100) including a reservoir (104/106, 108) including a strain gauge bonded to an outer surface thereof (see paragraph 44, Figs. 5A and 5B). Shih teaches that this allows for reservoir volume determinations via detection of the strain (see paragraph 41 for general discussion). Furthermore, Shih teaches detection of malfunctions with the strain gauge or other system sensors (paragraph 50). One of ordinary skill in the art would have found it obvious before the effective filing date of the application to provide a reservoir with an embedded strain gauge as taught by Shih in order to allow for further detection of malfunctions. Regarding claim 17, Neftel teaches securing the occlusion sensor at least indirectly to all parts, including a mid-section, of the outer surface of the flexible reservoir. Shih teaches securing the occlusion sensor directly to a mid-section (see e.g. Fig. 7A). Regarding claim 18, measurement of axial tension and compression along at least some axis is inherent in the operation of a strain gauge (Neftel, paragraph 130). Additionally, such is taught by Shih (paragraph 41). Regarding claim 19, Neftel teaches that the occlusion is detected when the resistance does not decay according to a designated pattern (paragraph 354, e.g. decreasing resistance). Response to Arguments Applicant’s arguments, see page 5, filed 29 September 2026, with respect to the rejection(s) of claim(s) 1 and 5-19 under 35 U.S.C. 102(a)(1) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Shih, as discussed above. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PHILIP E STIMPERT whose telephone number is (571)270-1890. The examiner can normally be reached Monday-Friday, 8a-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PHILIP E STIMPERT/Primary Examiner, Art Unit 3783 26 June 2026
Read full office action

Prosecution Timeline

Show 1 earlier event
Dec 23, 2025
Non-Final Rejection (signed) — §102, §103
Feb 03, 2026
Non-Final Rejection mailed — §102, §103
Apr 20, 2026
Response Filed
Jun 29, 2026
Final Rejection mailed — §102, §103
Aug 26, 2026
Response after Non-Final Action
Sep 29, 2026
Request for Continued Examination
Oct 07, 2026
Response after Non-Final Action
Oct 27, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788436
DEVICES AND METHODS FOR LAPAROSCOPIC ACCESS AND WOUND CLOSURE
3y 11m to grant Granted Nov 10, 2026
Patent 12779105
FLUID MANAGEMENT SYSTEM
4y 5m to grant Granted Nov 03, 2026
Patent 12766305
CLAMP
4y 0m to grant Granted Oct 20, 2026
Patent 12766259
BLOOD GLUCOSE CONTROL SYSTEM AND METHOD
3y 7m to grant Granted Oct 20, 2026
Patent 12752050
INFUSION PUMP
3y 9m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+48.8%)
3y 6m (~2m remaining)
Median Time to Grant
High
PTA Risk
Based on 902 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month